LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia

Journal of Lipid Research

Volumn 53, Issue 3, 2012, Pages 556-560

  Brautbar, Ariel ^a,b   Virani, Salim S ^b,c,d   Belmont, John ^b   Nambi, Vijay ^b,c   Jones, Peter H ^b,c   Ballantyne, Christie M ^b,c  

^a MARSHFIELD CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apolipoproteins; Fibrates; Genetic variants; HDL C; Pharmacogenetics

Indexed keywords

APOLIPOPROTEIN C; ASPARAGINE; ASPARTIC ACID; ATORVASTATIN; CHOLINE FENOFIBRATE; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

APOLIPOPROTEIN C-III; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN LIPASE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 84857703106     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M020404     Document Type: Article

References (30)

1. Gangabadage, C. S., J. Zdunek, M. Tessari, S. Nilsson, G. Olivecrona, and S. S. Wijmenga. 2008. Structure and dynamics of human apolipoprotein CIII. J. Biol. Chem. 283: 17416-17427.
2. Pollin, T. I., C. M. Damcott, H. Shen, S. H. Ott, J. Shelton, R. B. Horenstein, W. Post, J. C. McLenithan, L. F. Bielak, P. A. Peyser, et al. 2008. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 322: 1702-1705.
3. Kawakami, A., and M. Yoshida. 2009. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J. Atheroscler. Thromb. 16: 6-11.
4. van Raalte, D. H., M. Li, P. H. Pritchard, and K. M. Wasan. 2004. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharm. Res. 21: 1531-1538. (Pubitemid 41184380)
5. Ellen, R. L., and R. McPherson. 1998. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol. 81: 60B-65B. (Pubitemid 28113948)
6. Grundy, S. M., G. L. Vega, Z. Yuan, W. P. Battisti, W. E. Brady, and J. Palmisano. 2005. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95: 462-468. (Pubitemid 40247539)
7. ACCORD Study Group. 2010. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1563-1574.
8. Brautbar, A., D. Covarrubias, J. Belmont, F. Lara-Garduno, S. S. Virani, P. H. Jones, S. M. Leal, and C. M. Ballantyne. 2011. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 219: 737-742.
9. Jones, P. H., H. E. Bays, M. H. Davidson, M. T. Kelly, S. M. Buttler, C. M. Setze, D. J. Sleep, and J. C. Stolzenbach. 2008. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin. Drug Investig. 28: 625-634.
10. Kane, J. P., and R. J. Havel. 2001. Introduction: structure and metabolism of plasma lipoproteins. In Metabolic and molecular bases of inherited disease. C. R. Scriver, W. S. Sly, and B. Childs, editors. McGraw-Hill, New York. Ch.114. Accessed at www.ommbid.com.
11. Kathiresan, S., C. J. Willer, G. M. Peloso, S. Demissie, K. Musunuru, E. E. Schadt, L. Kaplan, D. Bennett, Y. Li, T. Tanaka, et al. 2009. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41: 56-65.
12. Willer, C. J., S. Sanna, A. U. Jackson, A. Scuteri, L. L. Bonnycastle, R. Clarke, S. C. Heath, N. J. Timpson, S. S. Najjar, H. M. Stringham, et al. 2008. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40: 161-169. (Pubitemid 351171403)
13. Spirin, V., S. Schmidt, A. Pertsemlidis, R. S. Cooper, J. C. Cohen, and S. R. Sunyaev. 2007. Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. Am. J. Hum. Genet. 81: 1298-1303. (Pubitemid 350211459)
14. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788. (Pubitemid 351846853)
15. Seldin, M. F., R. Shigeta, P. Villoslada, C. Selmi, J. Tuomilehto, G. Silva, J. W. Belmont, L. Klareskog, and P. K. Gregersen. 2006. European population substructure: clustering of northern and southern populations. PLoS Genet. 2: e143.
16. R Development Core Team. 2011. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
17. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81: 559-575. (Pubitemid 47330214)
18. Jong, M. C., M. H. Hofker, and L. M. Havekes. 1999. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19: 472-484. (Pubitemid 29135144)
19. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790-793.
20. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616. (Pubitemid 24293564)
21. Chan, D. C., M. M. Chen, E. M. Ooi, and G. F. Watts. 2008. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int. J. Clin. Pract. 62: 799-809. (Pubitemid 351533666)
22. Masucci-Magoulas, L., I. J. Goldberg, C. L. Bisgaier, H. Serajuddin, O. L. Francone, J. L. Breslow, and A. R. Tall. 1997. A mouse model with features of familial combined hyperlipidemia. Science. 275: 391-394. (Pubitemid 27051617)
23. Miller, M., C. P. Cannon, S. A. Murphy, J. Qin, K. K. Ray, and E. Braunwald. 2008. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 51: 724-730. (Pubitemid 351221217)
24. Superko, H. R. 1996. Beyond LDL cholesterol reduction. Circulation. 94: 2351-2354. (Pubitemid 26403555)
25. FIELD Study Investigators. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet. 366: 1849-1861.
26. Scott, R., R. O'Brien, G. Fulcher, C. Pardy, M. D'Emden, D. Tse, M. R. Taskinen, C. Ehnholm, and A. Keech. 2009. Effects of fenofi brate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 32: 493-498.
27. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfi brozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245. (Pubitemid 17147964)
28. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341: 410-418. (Pubitemid 29362514)
29. Sacks, F. M., P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald. 2000. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:1886-1892.
30. Kawakami, A., M. Osaka, M. Tani, H. Azuma, F. M. Sacks, K. Shimokado, and M. Yoshida. 2008. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation. 118: 731-742.